History

Corporate Milestone
2016
Feb
JW Therapeutics founded in Shanghai
Jul
GMP cell therapy manufacturing infrastructure first put into use
2017
Jul
World-class CAR-T technology platform introduced and technology development completed
2018
May
Completed series A financing totaling over USD100 million
Sep
JW Therapeutics (Suzhou) Co., Ltd. founded
Nov
World-leading commercial scale cell therapy manufacturing project started
Dec
JW Therapeutics R&D center opened
2019
Feb
Recognized as a “Foreign-invested R&D center” by Shanghai Municipal People’s Government
Dec
Cell therapy commercial scale manufacturing infrastructure completed in Suzhou
Dec
GMP quality management lab put into use
2020
May
Completed USD100 million series B financing
Jun
Acquired Syracuse Biopharma
Jun
Suzhou site obtained drug manufacturing license
Nov
Listed on the main board of the Hong Kong Stock Exchange, stock code 2126.HK
Product Milestone
2017
Dec
First Chinese patient received relma-cel* infusion therapy
2018
Jun
Relma-cel obtained first approval for clinical trial of CAR-T product targeting CD19 under IND pathway in China
2019
Apr
Successfully introduced BCMA-targeted cell therapy drug candidate (codename: JWCAR129)
Jun
Included in the National Significant New Drug Development Program
2020
Jun
Relma-cel’s new drug application for its first indication formally accepted
Sep
Relma-cel granted priority review for its new drug application, and Breakthrough Therapy Designation as a treatment for FL by NMPA

* Relmacabtagene autoleucel (relma-cel): JW Therapeutics’ lead product under development (codename: JWCAR029)